Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition

被引：61

作者：

Kim, Hye-Jung ^{[1
,2
]}

Cantor, Harvey ^{[1
,2
]}

Cosmopoulos, Kat ^{[3
]}

机构：

[1] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA

[2] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA

[3] Epizyme Inc, Cambridge, MA 02139 USA

来源：

TRENDS IN IMMUNOLOGY | 2020年 / 41卷 / 10期

基金：

美国国家卫生研究院;

关键词：

REGULATORY T-CELLS; METHYLTRANSFERASE GENE EZH2; SOMATIC MUTATIONS; DNA METHYLATION; CANCER-IMMUNITY; PROTEIN EZH2; LYSINE; 27; POLYCOMB; IMMUNOTHERAPY; DIFFERENTIATION;

D O I：

10.1016/j.it.2020.08.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Recent progress in cancer immunotherapy highlights the power of the immune system to control tumors, although a small patient subset responds to current immunotherapies. Additional approaches to mobilize antitumor immunity are required to overcome primary and acquired resistance to immunotherapy such as immune checkpoint blockade (ICB). Emerging evidence shows that targeting epigenetic elements that promote tumor progression and inhibit immune cell activity can enhance antitumor immunity by reshaping the tumor microenvironment (TME). Here, we review the pleiotropic functions in tumor and immune cells of enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 (PRC2), with a focus on EZH2 inhibition as a potentially promising approach to enhance current immunotherapies and improve patient outcomes for certain cancers.

引用

页码：948 / 963

页数：16

共 50 条

[41] Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS [J].

Ciarapica, Roberta ;

Carcarino, Elena ;

Adesso, Laura ;

De Salvo, Maria ;

Bracaglia, Giorgia ;

Leoncini, Pier Paolo ;

Dall'Agnese, Alessandra ;

Verginelli, Federica ;

Milano, Giuseppe M. ;

Boldrini, Renata ;

Inserra, Alessandro ;

Stifani, Stefano ;

Screpanti, Isabella ;

Marquez, Victor E. ;

Valente, Sergio ;

Mai, Antonello ;

Puri, Pier Lorenzo ;

Locatelli, Franco ;

Palacios, Daniela ;

Rota, Rossella .

BMC CANCER, 2014, 14

[42] Biological mechanisms of resistance to immune checkpoint inhibitors and overcoming this resistance: Challenges in medical oncology [J].

Moskalenko, Y. .

REGULATORY MECHANISMS IN BIOSYSTEMS, 2024, 15 (01) :83-91

[43] Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2 [J].

Yang, Jing ;

Weisberg, Ellen L. ;

Qi, Shuang ;

Ni, Wei ;

Mei, Husheng ;

Wang, Zuowei ;

Meng, Chengcheng ;

Zhang, Shengzhe ;

Hou, Mingqi ;

Qi, Ziping ;

Wang, Aoli ;

Jiang, Yunyun ;

Jiang, Zongru ;

Huang, Tao ;

Liu, Qingwang ;

Magin, Robert S. ;

Doherty, Laura ;

Wang, Wenchao ;

Liu, Jing ;

Buhrlage, Sara J. ;

Liu, Qingsong ;

Griffin, James D. .

LEUKEMIA, 2022, 36 (04) :1048-1057

[44] Inhibition of EZH2 Enhances the Antitumor Efficacy of Metformin in Prostate Cancer [J].

Kong, Yifan ;

Zhang, Yanquan ;

Mao, Fengyi ;

Zhang, Zhuangzhuang ;

Li, Zhiguo ;

Wang, Ruixin ;

Liu, Jinghui ;

Liu, Xiaoqi .

MOLECULAR CANCER THERAPEUTICS, 2020, 19 (12) :2490-2501

[45] A non-canonical function of Ezh2 preserves immune homeostasis [J].

Vasanthakumar, Ajithkumar ;

Xu, Dakang ;

Lun, Aaron T. L. ;

Kueh, Andrew J. ;

van Gisbergen, Klaas P. J. M. ;

Iannarella, Nadia ;

Li, Xiaofang ;

Yu, Liang ;

Wang, Die ;

Williams, Bryan R. G. ;

Lee, Stanley C. W. ;

Majewski, Ian J. ;

Godfrey, Dale I. ;

Smyth, Gordon K. ;

Alexander, Warren S. ;

Herold, Marco J. ;

Kallies, Axel ;

Nutt, Stephen L. ;

Allan, Rhys S. .

EMBO REPORTS, 2017, 18 (04) :619-631

[46] Inhibition of EZH2 transactivation function sensitizes solid tumors to stress [J].

Liao, Yiji ;

Chen, Chen-Hao ;

Xiao, Tengfei ;

Avalos, Barbara de la Pena ;

Dray, Eloise, V ;

Cai, Changmeng ;

Gao, Shuai ;

Shah, Neel ;

Zhang, Zhao ;

Feit, Avery ;

Xue, Pengya ;

Liu, Zhijie ;

Yang, Mei ;

Lee, Ji Hoon ;

Xu, Han ;

Li, Wei ;

Mei, Shenglin ;

Pierre, Roodolph S. ;

Shu, Shaokun ;

Fei, Teng ;

Duarte, Melissa ;

Zhao, Jin ;

Bradner, James E. ;

Polyak, Kornelia ;

Kantoff, Philip W. ;

Long, Henry ;

Balk, Steven P. ;

Liu, X. Shirley ;

Brown, Myles ;

Xu, Kexin .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (03)

[47] The Effect of Direct and Indirect EZH2 Inhibition in Rhabdomyosarcoma Cell Lines [J].

Schmidt, Andreas ;

Behrendt, Lucas ;

Eybe, Jana ;

Warmann, Steven W. ;

Schleicher, Sabine ;

Fuchs, Joerg ;

Schmid, Evi .

CANCERS, 2022, 14 (01)

[48] Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS [J].

Roberta Ciarapica ;

Elena Carcarino ;

Laura Adesso ;

Maria De Salvo ;

Giorgia Bracaglia ;

Pier Paolo Leoncini ;

Alessandra Dall’Agnese ;

Federica Verginelli ;

Giuseppe M Milano ;

Renata Boldrini ;

Alessandro Inserra ;

Stefano Stifani ;

Isabella Screpanti ;

Victor E Marquez ;

Sergio Valente ;

Antonello Mai ;

Pier Lorenzo Puri ;

Franco Locatelli ;

Daniela Palacios ;

Rossella Rota .

BMC Cancer, 14

[49] Resistance to systemic immune checkpoint inhibition in the peritoneal niche [J].

Chia, Daryl Kai Ann ;

Gwee, Yong Xiang ;

Sundar, Raghav .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)

[50] Targeting glioma stem cells through combined BMI1 and EZH2 inhibition [J].

Jin, Xun ;

Kim, Leo J. Y. ;

Wu, Qiulian ;

Wallace, Lisa C. ;

Prager, Briana C. ;

Sanvoranart, Tanwarat ;

Gimple, Ryan C. ;

Wang, Xiuxing ;

Mack, Stephen C. ;

Miller, Tyler E. ;

Huang, Ping ;

Valentim, Claudia L. ;

Zhou, Qi-gang ;

Barnholtz-Sloan, Jill S. ;

Bao, Shideng ;

Sloan, Andrew E. ;

Rich, Jeremy N. .

NATURE MEDICINE, 2017, 23 (11) :1352-+

← 1 2 3 4 5 →